

To,
The Manager, Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street – Fort
Mumbai 400 001
Scrip Code: 544578

To,
The Manager, Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th floor, Plot no. C/1, G Block
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051
NSE Symbol: RUBICON

Date: 30th October, 2026

ISIN - INE506V01022

Subject: : Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Outcome of USFDA inspection of the company's manufacturing facility in Ambernath, India

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration (US FDA) conducted an unannounced inspection (triggered by a product filing) of the company's manufacturing facility located at Plot No. K30/4 & 30/5, Additional M.I.D.C., Anand Nagar, Ambernath, Maharashtra, India from Wednesday, 21 October 2026 to Thursday, 29 October 2026. This was a comprehensive GMP inspection in addition to the product application under review.

Upon conclusion, a Form 483 containing 3 observations with respect to system improvement and 2 observations with respect to product application under review were issued, all 5 of which are procedural in nature and do not relate to data integrity. The company is confident of working closely with the regulator to successfully conclude the evaluation in a timely manner.

All our manufacturing as well as R&D facilities have now been inspected by the US FDA in the recent past and the table below summarizes the status of all our operational facilities:

Facility	Month of Inspection	Nature of Inspection	Outcome	Remarks
R&D				
Canada	Apr-26	Unannounced	Zero Observations	EIR Received
Thane	Mar-25	Announced	Zero Observations	EIR Received
Manufacturing				
New Jersey, USA	May-26	Prior to our acquisition	Six Observations during inspection under previous owner just about a month before our acquisition	EIR Received with VAI status
Ambernath	Oct-26	Unannounced	Three observations with respect to system improvement and Two observations with respect to product application under review were issued, all Five of which are procedural in nature and do not relate to data integrity	We are confident of working closely with the regulator to successfully conclude the evaluation in a timely manner.
Pithampur	Jul-26	Unannounced	Two Observations, procedural in nature and do not relate to data integrity	Response submitted in Jul-26. EIR awaited
Satara	Oct-26	Unannounced	One Observation, procedural in nature and does not relate to data integrity	We are confident of working closely with the regulator to successfully conclude the evaluation in a timely manner

We will keep the stock exchanges duly informed of any further updates on this subject. Kindly take the above intimation on record.

Yours faithfully,
For Rubicon Research Limited

DEEPASHR
EE OMKAR
TANKSALE

Deepashree Tanksale
Company Secretary
M. No. A28132

Digitally signed by DEEPASHREE OMKAR
TANKSALE
DN: cn=PERSONAL, o=9602,
c=IN, email=DEEPASHREE.OMKAR@RUBICON.CO.IN,
serial=409003, serialNumber=409003, serialNumber=409003,
c=IN, email=DEEPASHREE.OMKAR@RUBICON.CO.IN,
Date: 2026.10.30 00:05:32 +05'30'